Outcome predictors in acute severe ulcerative colitis
- PMID: 37365074
- DOI: 10.1016/j.dld.2023.06.012
Outcome predictors in acute severe ulcerative colitis
Conflict of interest statement
Conflicts of interest MBA has received financial support for travelling and educational activities from or has served as an advisory board member for Pfizer, MSD, Takeda, AbbVie, Kern, Janssen, Fresenius Kabi, Galapagos, Lilly, BMS, Roche, Ferring, Faes Farma, Biogen, Amgen, Chiesi and Adacyte. AA has received consulting and/or advisory board fees from AbbVie, Allergan, Amgen, Arena, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mylan, Pfizer, Protagonist Therapeutics, Roche, Samsung Bioepis, Sandoz, and Takeda; lecture and/or speaker bureau fees from AbbVie, Amgen, Arena, Biogen, Bristol-Myers Squibb, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mitsubishi Tanabe, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, and Tigenix; and research grants from MSD, Pfizer, Takeda and Biogen.
Comment on
-
Deep ulcers are associated with increased C-reactive protein in active ulcerative colitis.Dig Liver Dis. 2023 Sep;55(9):1194-1200. doi: 10.1016/j.dld.2023.05.004. Epub 2023 May 25. Dig Liver Dis. 2023. PMID: 37244790
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
